The world’s only searchable, sortable database of 300+ investors who are actively investing in regenerative medicine (RM) and advanced therapy (AT) companies.
Regenerative medicine companies are those involved with cell therapies, gene therapies, exosomes, tissue engineering, biomaterials, or other therapies involving the use of human cells and tissues.
To develop these novel products, investor capital is often needed to support these therapies from preclinical development through clinical trials, and ultimately, to commercialization. Regenerative medicine investors include:- Venture Capital Groups
- Private Equity Firms
- Hedge Funds
- Investment Firms
- Endowment Funds
- Family Offices
- Angel Investors
This database reveals the identity and investment behavior of 300+ investors who specialize in companies commercializing regenerative medicine (RM) and advanced therapy (AT) products. It is designed to be used by companies who are pursuing or considering a capital raise, including:- Seed rounds
- Venture rounds
- Private placements
- Loans and convertible debt
- Any expansion or company growth requiring outside funding
It took our analysts hundreds of hours of research to uncover these RM investors from across the globe. In addition to diligently searching through hundreds of resources, we utilized translators and crowd-sourced feedback from BioInformant’s partners, clients, and readership.
This database also includes little known investors that would be difficult to identify if you had not been tracking this industry daily for the past 19+ years (as BioInformant has done).
If you are in the process of raising investor capital for your company, product candidate, or clinical trial, then this database is a must-have.
For 48 hours only, you can claim it for an unusual $150 off:
Remember to act fast, because the offer expires soon.
Be Great, The BioInformant Team
p.s. Interested in other market areas, such as iPSCs, CAR-T, Exosomes, Cord Blood & Tissue, Regenerative Medicine, and beyond?
|
